To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
APV (NMDAR antagonist)
Additional recommended knowledge
APV (2-amino-5-phosphonovaleric acid; AP5, 2-amino-5-phosphonopentanoate) is a selective NMDA receptor (NMDAR) antagonist that competitively inhibits the active site of NMDAR. Its chemical name is R-2-amino-5-phosphonopentanoate.
APV blocks the cellular analog of classical conditioning in the sea slug Aplysia californica, and has similar effects on Aplysia long-term potentiation, since NMDA receptors are required for both. It is sometimes used in conjunction with the calcium chelator BAPTA to determine whether NMDARs are required for a particular cellular process.
APV is generally very fast acting within in vitro preparations, and can block NMDA receptor action at a reasonably small concentration. The active isomer of APV is considered to be the D configuration, although many preparations are available as a racemic mixture of D- and L-isomers. It is useful to isolate the action of other glutamate receptors in the brain, i.e. AMPA and kainate receptors.
APV can block the conversion of a silent synapse to an active one, since this conversion is NMDA receptor-dependent.
APV was developed by Jeff Watkins and Harry Olverman.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "APV_(NMDAR_antagonist)". A list of authors is available in Wikipedia.|